14

AAO 2024 Day 4 Wrap-Up: Another Year in the Books

All’s well that ends well here in Chicago, and AAO 2024 Day 4 certainly qualifies as ending well. We recap our final day of coverage, including some late-breaking FDA news from LENZ Therapeutics.

The sounds of hammers, saws and other miscellaneous construction implements in the exhibition hall of the McCormick Place Convention Center in Chicago can only mean one thing: The 128th Annual Meeting of the American Academy of Ophthalmologists (AAO 2024) is over.

And what a long weekend of ophthalmic scholarship and innovation it was, with more than 600 sessions on the docket this year across four days of unseasonably beautiful, sunny fall weather in the (not so) Windy City. 

Doctors and industry representatives from around the world came together to share experiences, showcase innovations, and, yes, debate some of the eye care world’s hottest controversies. 

Buzzworthy topics this year included the usuals like artificial intelligence—but also fiercely contentious newcomers like complement inhibitors in geographic atrophy, for-profit cornea banking, novel cornea transplant technologies and many more. Be sure to check out our previous coverage for the latest on these issues.

Day 4 was a short day of sessions, and the editorial team covered two sessions for our curtain call here in Chicago. 

In the first, women luminaries from across the eye care world teamed up for some seriously practical tips on how women can overcome obstacles to get theirs in ophthalmology. From learning how to say ‘no’, to pathways to promotions via academia and learning the art of negotiation, there are an abundance of takeaways here to smash through the glass ceiling and put your career on the trajectory it deserves. 

Our second highlight session was another pearl-packed endeavor, but of a completely different variety. General ophthalmologists will want to dive into this one, as it’s full of immediately practicable tips from the world of ocular oncology. In its twelfth year at AAO, this course was full of wisdom on maladies from vitreoretinal lymphomas to retinoblastomas, including things you can do now to save sight and lives for your patients. 

So be sure to check out these articles—and the rest of our daily AAO 2024 coverage—for all the highlights from global ophthalmology’s marquee conference. From all the Media MICE team, thanks for tuning in as always, and see you next year in Orlando!

Industry Update: LENZ Therapeutics

Earlier today, LENZ Therapeutics (Del Mar, USA; NASDAQ: LENZ) announced that the FDA has accepted its New Drug Application (NDA) for the firm’s presbyopia eye drop candidate LNZ100. The FDA has set a Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025. PDUFA action dates are often used as a proxy for FDA approval decision timelines.

“With the acceptance of our New Drug Application for LNZ100, we are pleased to be one step closer towards potential approval and look forward to continuing to collaborate with the FDA to deliver the first once-daily, well-tolerated and rapid acting eye drop for the treatment of presbyopia to the 128 million individuals living with blurry near vision in the United States,” Lenz Therapeutics CEO Eef Schimmelpennink said in a statement.

Editor’s Note: Reporting for this story took place during the 128th Annual Meeting of the American Academy of Ophthalmology (AAO 2024) from 18-21 October in Chicago, Illinois, USA.

Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments